TN2009000149A1 - 2- [l-phenyl-5-hydroxy-4 alpha-methyl-hexahydrocyclopenta [f] indazol-5-yl] ethyl phenyl derivatives as glucocorticoid receptor ligands - Google Patents

2- [l-phenyl-5-hydroxy-4 alpha-methyl-hexahydrocyclopenta [f] indazol-5-yl] ethyl phenyl derivatives as glucocorticoid receptor ligands

Info

Publication number: TN2009000149A1
Authority: TN; Tunisia
Prior art keywords: phenyl; indazol; hydroxy; methyl; glucocorticoid receptor
Prior art date: 2006-10-23

Application number

TNP2009000149A

Other languages

English (en)

Inventor

Christopher J Bungard

Jesse J Manikowski

James J Perkins

Robert Meissner

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-23

Filing date

2009-04-21

Publication date

2010-10-18

2009-04-21 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2010-10-18 Publication of TN2009000149A1 publication Critical patent/TN2009000149A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Virology (AREA)
Hematology (AREA)
Oncology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Otolaryngology (AREA)
Heart & Thoracic Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Addiction (AREA)
Biotechnology (AREA)

TNP2009000149A 2006-10-23 2009-04-21 2- [l-phenyl-5-hydroxy-4 alpha-methyl-hexahydrocyclopenta [f] indazol-5-yl] ethyl phenyl derivatives as glucocorticoid receptor ligands TN2009000149A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US85365506P	2006-10-23	2006-10-23
US92333707P	2007-04-13	2007-04-13
PCT/US2007/022449 WO2008060391A2 (fr)	2006-10-23	2007-10-23	DÉRIVÉS DE 2-[1-PHÉNYL-5-HYDROXY OU MÉTHOXY-4-ALPHA-MÉTHYL-HEXAHYDROCYCLOPENTA[f]INDAZOL-5-YL]ÉTHYLE PHÉNYLE EN TANT QUE LIGANDS DU RÉCEPTEUR DE GLUCOCORTICOÏDE

Publications (1)

Publication Number	Publication Date
TN2009000149A1 true TN2009000149A1 (en)	2010-10-18

Family

ID=39030900

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000149A TN2009000149A1 (en)	2006-10-23	2009-04-21	2- [l-phenyl-5-hydroxy-4 alpha-methyl-hexahydrocyclopenta [f] indazol-5-yl] ethyl phenyl derivatives as glucocorticoid receptor ligands

Country Status (19)

Country	Link
US (1)	US8119681B2 (fr)
EP (2)	EP2097385B1 (fr)
JP (1)	JP5271911B2 (fr)
KR (1)	KR20090068345A (fr)
CN (1)	CN101528707B (fr)
AT (1)	ATE538099T1 (fr)
AU (1)	AU2007309507A1 (fr)
BR (1)	BRPI0718505A2 (fr)
CA (1)	CA2667007A1 (fr)
CO (1)	CO6190517A2 (fr)
CR (1)	CR10771A (fr)
EA (1)	EA200970401A1 (fr)
IL (1)	IL198226A0 (fr)
MA (1)	MA30870B1 (fr)
MX (1)	MX2009004385A (fr)
NO (1)	NO20092004L (fr)
SV (1)	SV2009003233A (fr)
TN (1)	TN2009000149A1 (fr)
WO (2)	WO2008051532A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200829578A (en)	2006-11-23	2008-07-16	Astrazeneca Ab	Chemical compounds 537
JO2754B1 (en)	2006-12-21	2014-03-15	استرازينكا ايه بي	Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
ES2626131T3 (es) *	2007-10-17	2017-07-24	Laboratoire Hra Pharma	Antagonistas del receptor de glucocorticoides tales como mifepristona para tratar el síndrome de Cushing
EP2212294A1 (fr) *	2007-10-23	2010-08-04	Merck Sharp & Dohme Corp.	Procédé de préparation de ligands du récepteur des glucocorticoïdes
UY31832A (es)	2008-05-20	2010-01-05	Astrazeneca Ab	Derivados de indazol sustituidos con fenilo y benzodioxinilo
WO2010138421A1 (fr) *	2009-05-27	2010-12-02	Merck Sharp & Dohme Corp.	Amides inverses d'hexahydrocyclopentyl[f]indazole et leurs dérivés comme modulateurs sélectifs du récepteur des glucocorticoïdes
WO2010141247A1 (fr)	2009-06-02	2010-12-09	Merck Sharp & Dohme Corp.	Hexahydrocyclopentyl[∫]indazole-5-hydroxyméthyléthanols et dérivés de ceux-ci en tant que modulateurs des récepteurs glucocorticoïdes sélectifs
US20120172397A1 (en) *	2009-09-08	2012-07-05	Merck Sharp & Dohme Corp.	HEXAHYDROCYCLOPENTA[f]INDAZOLE 5-YL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
US20120214847A1 (en) *	2009-10-30	2012-08-23	Merck Sharp & Dohme Corp.	2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS
HK1203412A1 (en)	2011-12-28	2015-10-30	Global Blood Therapeutics, Inc.	Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
SG10201912411RA (en)	2011-12-28	2020-02-27	Univ California	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US9802900B2 (en)	2013-03-15	2017-10-31	Global Blood Therapeutics, Inc.	Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en)	2013-03-15	2014-09-18	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en)	2013-03-15	2016-08-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
EP2970196B1 (fr)	2013-03-15	2020-11-25	Global Blood Therapeutics, Inc.	Composés et leurs utilisations pour la modulation de l'hémoglobine
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en)	2013-03-15	2018-10-16	Global Blood Therapeutics, Inc.	Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
KR20150132146A (ko)	2013-03-15	2015-11-25	글로벌 블러드 테라퓨틱스, 인크.	헤모글로빈 조정을 위한 화합물 및 이의 용도
US9604999B2 (en)	2013-03-15	2017-03-28	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
BR112015021982B1 (pt)	2013-03-15	2022-12-13	Global Blood Therapeutics, Inc	Compostos e seus usos para a modulação de hemoglobina
US10266551B2 (en)	2013-03-15	2019-04-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru)	2013-11-18	2021-09-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
FI3102208T4 (fi)	2014-02-07	2024-09-23	Global Blood Therapeutics Inc	2-hydroksi-6-((2-(1-isopropyyli-1h-pyratsol-5-yyli)pyridin-3-yyli)metoksi)bentsaldehydin vapaan emäksen kiteinen polymorfi
MA41841A (fr)	2015-03-30	2018-02-06	Global Blood Therapeutics Inc	Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
KR20180052120A (ko)	2015-08-13	2018-05-17	코어셉트 쎄라퓨틱스, 잉크.	Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
WO2017096230A1 (fr)	2015-12-04	2017-06-08	Global Blood Therapeutics, Inc.	Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
CA3011728A1 (fr)	2016-01-19	2017-07-27	Corcept Therapeutics, Inc.	Diagnostic differentiel du syndrome de cushing ectopique
AR108435A1 (es)	2016-05-12	2018-08-22	Global Blood Therapeutics Inc	Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TW202332423A (zh)	2016-10-12	2023-08-16	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US10195214B2 (en)	2017-03-01	2019-02-05	Corcept Therapeutics, Inc.	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
ES2966707T3 (es)	2018-10-01	2024-04-23	Global Blood Therapeutics Inc	Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
US20220227729A1 (en)	2019-05-21	2022-07-21	Bayer Aktiengesellschaft	Identification and use of kras inhibitors
CA3178756A1 (fr)	2020-05-27	2021-12-02	Hazel Hunt	Administration concomitante de relacorilant de modulateur du recepteur de glucocorticoide et de paclitaxel, double substrat de cyp2c8 et cyp3a4

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6846839B1 (en) *	1995-06-07	2005-01-25	Sugen, Inc.	Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
CA2473886C (fr) *	2002-01-22	2012-08-21	The Regents Of The University Of California	Ligands non steroidiens pour le recepteur des corticoides, compositions et utilisations desdits ligands
JP4570878B2 (ja) *	2002-04-11	2010-10-27	メルク・シャープ・エンド・ドーム・コーポレイション	選択的糖質コルチコイド受容体モジュレーターとしての１Ｈ−ベンゾ［ｆ］インダゾール−５−イル誘導体
AU2004216182B2 (en)	2003-02-25	2008-11-20	Merck Sharp & Dohme Corp.	Selective non-steroidal glucocorticoid receptor modulators
EP1617806B1 (fr) *	2003-04-23	2009-11-04	Merck & Co., Inc.	Modulateurs des recepteurs aux glucocorticoides spirocycliques selectifs

2007
- 2007-10-23 AT AT07867264T patent/ATE538099T1/de active
- 2007-10-23 CA CA002667007A patent/CA2667007A1/fr not_active Abandoned
- 2007-10-23 MX MX2009004385A patent/MX2009004385A/es unknown
- 2007-10-23 EP EP07839748A patent/EP2097385B1/fr active Active
- 2007-10-23 EP EP07867264A patent/EP2091922B1/fr not_active Withdrawn - After Issue
- 2007-10-23 US US12/445,901 patent/US8119681B2/en not_active Expired - Fee Related
- 2007-10-23 EA EA200970401A patent/EA200970401A1/ru unknown
- 2007-10-23 JP JP2009534622A patent/JP5271911B2/ja not_active Expired - Fee Related
- 2007-10-23 KR KR1020097008368A patent/KR20090068345A/ko not_active Withdrawn
- 2007-10-23 WO PCT/US2007/022463 patent/WO2008051532A1/fr not_active Ceased
- 2007-10-23 BR BRPI0718505-7A patent/BRPI0718505A2/pt not_active Application Discontinuation
- 2007-10-23 AU AU2007309507A patent/AU2007309507A1/en not_active Abandoned
- 2007-10-23 CN CN2007800392434A patent/CN101528707B/zh not_active Expired - Fee Related
- 2007-10-23 WO PCT/US2007/022449 patent/WO2008060391A2/fr not_active Ceased
2009
- 2009-04-19 IL IL198226A patent/IL198226A0/en unknown
- 2009-04-21 SV SV2009003233A patent/SV2009003233A/es not_active Application Discontinuation
- 2009-04-21 TN TNP2009000149A patent/TN2009000149A1/fr unknown
- 2009-04-22 CO CO09040679A patent/CO6190517A2/es not_active Application Discontinuation
- 2009-05-06 CR CR10771A patent/CR10771A/es not_active Application Discontinuation
- 2009-05-07 MA MA31847A patent/MA30870B1/fr unknown
- 2009-05-22 NO NO20092004A patent/NO20092004L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ATE538099T1 (de)	2012-01-15
CO6190517A2 (es)	2010-08-19
AU2007309507A1 (en)	2008-05-02
WO2008060391A3 (fr)	2008-09-25
WO2008060391A2 (fr)	2008-05-22
CR10771A (es)	2009-05-25
SV2009003233A (es)	2009-10-19
BRPI0718505A2 (pt)	2013-11-12
EP2091922B1 (fr)	2011-12-21
EP2097385A1 (fr)	2009-09-09
JP2010507663A (ja)	2010-03-11
EP2091922A2 (fr)	2009-08-26
CA2667007A1 (fr)	2008-05-02
US20100311709A1 (en)	2010-12-09
KR20090068345A (ko)	2009-06-26
MX2009004385A (es)	2009-05-22
IL198226A0 (en)	2009-12-24
MA30870B1 (fr)	2009-11-02
EP2097385B1 (fr)	2012-08-01
CN101528707A (zh)	2009-09-09
US8119681B2 (en)	2012-02-21
NO20092004L (no)	2009-07-22
WO2008051532A1 (fr)	2008-05-02
CN101528707B (zh)	2012-11-07
EA200970401A1 (ru)	2009-10-30
JP5271911B2 (ja)	2013-08-21

Publication	Publication Date	Title
TN2009000149A1 (en)	2010-10-18	2- [l-phenyl-5-hydroxy-4 alpha-methyl-hexahydrocyclopenta [f] indazol-5-yl] ethyl phenyl derivatives as glucocorticoid receptor ligands
HUS2100011I1 (hu)	2021-05-28	Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
TN2010000044A1 (en)	2011-09-26	Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MX2009006706A (es)	2009-07-02	Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
JO2761B1 (en)	2014-03-15	Derivatives of alcohols 1-phenyl-2-pyridinealkyl as inhibitors
IL182685A0 (en)	2007-09-20	Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
IL182527A0 (en)	2007-09-20	Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
PT2203478E (pt)	2014-02-25	Composições e métodos para uso de anticorpos contra esclerostina
ZA200807862B (en)	2009-06-24	Azolopyrimidines as inhibitors of cannabinoid 1 activity
EP2005168A4 (fr)	2009-05-20	Procedes et compositions destines au diagnostic de maladies de l'aorte
MX2009007104A (es)	2009-09-18	Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
IL176960A0 (en)	2006-12-10	Compositions and methods of treatment for inflammatory diseases
MX2009004746A (es)	2009-05-22	Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
IL198901A0 (en)	2010-02-17	Pyrimidine derivatives and multiple myeloma
EP2061788A4 (fr)	2010-10-06	Nouvelles compositions et procédés pour le traitement de maladies associées à des lymphocytes activés
ZA200703389B (en)	2009-12-30	Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
NO20091266L (no)	2009-06-09	Fremgangsmåter for administrering av langvarige hypoglykemiske midler
ATE517873T1 (de)	2011-08-15	6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
TNSN08244A1 (en)	2009-10-30	Process for the preparation of ferri-succinylcasein
SG158091A1 (en)	2010-01-29	Imidazoazepinone compounds
WO2009108525A3 (fr)	2010-01-07	Hexahydrocyclopentyl[f]indazole carboxamides et leurs dérivés comme modulateurs sélectifs du récepteur de glucocorticoïdes
EP1599201A4 (fr)	2007-01-24	Modulateurs selectifs de recepteurs de glucocorticoides non steroidaux
TW200734323A (en)	2007-09-16	3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
DE602007007934D1 (en)	2010-09-02	Imidazoazephinonverbindungen
MX2007010572A (es)	2007-10-04	Compuestos de cinolina y su uso como moduladores de receptor x de higado.